^
ER positive
Estrogen Receptor Positive Breast Cancer
MYCi975
Sensitive: D – Preclinical
Sci Adv - 3 weeks - (New D)
ER positive
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
exemestane
Sensitive: A1 - Approval
ER positive
Estrogen Receptor Positive Breast Cancer
toremifene
Sensitive: A1 - Approval
ER mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: B - Late Trials
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: B - Late Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: B - Late Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
exemestane
Resistant: B - Late Trials
HSD17B2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
IGFBP7 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: B - Late Trials
ER positive
Estrogen Receptor Positive Breast Cancer
RAD1901
Sensitive: B - Late Trials
ESR1 mutation
Estrogen Receptor Positive Breast Cancer
palbociclib
Sensitive: B - Late Trials
ER positive
Estrogen Receptor Positive Breast Cancer
Z-endoxifen hydrochloride
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
SAR439859
Sensitive: C2 – Inclusion Criteria
CCND1 amplification
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C2 – Inclusion Criteria
ER-L
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
alpelisib
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
abemaciclib
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
ribociclib
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
anastrozole
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
letrozole
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
RG4733
Sensitive: C2 – Inclusion Criteria
ER positive
Estrogen Receptor Positive Breast Cancer
SNDX-275
Sensitive: C2 – Inclusion Criteria
EPRS1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
FTO expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
CTDSP1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
BIN3 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
bevacizumab
Sensitive: C3 – Early Trials
ER Y537S
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: C3 – Early Trials
CDK6 overexpression
Estrogen Receptor Positive Breast Cancer
fulvestrant
Resistant: C3 – Early Trials
RSF1 amplification
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
AURKA overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
NOS2 underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
HPGD underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
CCNE1 overexpression
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
CDK2 overexpression
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
CCNE1-H
Estrogen Receptor Positive Breast Cancer
palbociclib
Resistant: C3 – Early Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
enobosarm
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + CB-228
Sensitive: C3 – Early Trials
76-gene signature
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
RET overexpression
Estrogen Receptor Positive Breast Cancer
vandetanib
Sensitive: C3 – Early Trials
RET overexpression
Estrogen Receptor Positive Breast Cancer
fulvestrant
Sensitive: C3 – Early Trials
FOXD1 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
tamoxifen + GDC-0032
Sensitive: C3 – Early Trials
WSB2 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
PIK3CA mutation
Estrogen Receptor Positive Breast Cancer
letrozole
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
venetoclax
Sensitive: C3 – Early Trials
CCND1 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
AGR2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
CCNB2 expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
BCL2 positive
Estrogen Receptor Positive Breast Cancer
venetoclax
Sensitive: C3 – Early Trials
AKT1 E17K
Estrogen Receptor Positive Breast Cancer
AZD5363
Sensitive: C3 – Early Trials
NCOR2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
35-gene signature
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Resistant: C3 – Early Trials
35-gene signature
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Resistant: C3 – Early Trials
KDR V297I
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
SLBP expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
RBPMS expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
ixazomib
Sensitive: C3 – Early Trials
SOX9 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
RUNX3 underexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
ponatinib
Sensitive: C3 – Early Trials
IL6R overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
PTEN mutation
Estrogen Receptor Positive Breast Cancer
AZD5363
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
MLN8237
Sensitive: C3 – Early Trials
ER mutation
Estrogen Receptor Positive Breast Cancer
bevacizumab
Sensitive: C3 – Early Trials
AR positive
Estrogen Receptor Positive Breast Cancer
enobosarm
Sensitive: C3 – Early Trials
ER overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
sunitinib
Sensitive: C3 – Early Trials
NODAL overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
SALL4 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
TRIM3 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
AGR2-H
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
SOX2 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
ASXL1 mutation
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Sensitive: C3 – Early Trials
ASXL1 mutation
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Sensitive: C3 – Early Trials
BRCA2 overexpression
Estrogen Receptor Positive Breast Cancer
olaparib
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
palbociclib + PF-05212384
Sensitive: C3 – Early Trials
EZH2 rs201135441C>T
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
pyrotinib + letrozole
Sensitive: C3 – Early Trials
PPP3CA expression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
HER-2 mutation
Estrogen Receptor Positive Breast Cancer
trastuzumab + neratinib
Sensitive: C3 – Early Trials
HER-2 mutation
Estrogen Receptor Positive Breast Cancer
neratinib
Sensitive: C3 – Early Trials
LAMTOR5 overexpression
Estrogen Receptor Positive Breast Cancer
tamoxifen
Resistant: C3 – Early Trials
ESR1 rs9322354
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ESR1 rs2228480
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ESR1 rs1801132
Estrogen Receptor Positive Breast Cancer
tamoxifen
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
CDK6 inhibitor
Sensitive: C3 – Early Trials
ER positive
Estrogen Receptor Positive Breast Cancer
CDK4 inhibitor
Sensitive: C3 – Early Trials
HER-2 mutation
Estrogen Receptor Positive Breast Cancer
tucatinib
Sensitive: C4 – Case Studies
ER positive
Estrogen Receptor Positive Breast Cancer
apalutamide
Sensitive: D – Preclinical